ArticleFrontiers in oncology2023

Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study.

Ya Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.